RecruitingNot ApplicableNCT06833450
Reliability of IUS in Crohn's Disease
Sponsor
Centre Hospitalier Universitaire, Amiens
Enrollment
30 participants
Start Date
Jan 19, 2022
Study Type
INTERVENTIONAL
Conditions
Summary
Transabdominal intestinal ultrasound (IUS) is gaining acceptance as a point-of-care test to objectively assess disease activity in Crohn's disease (CD). In order to incorporate individual parameters in a future definition of transmural healing, and for the consistent application of IUS as a modality to assess treatment outcomes and establish therapeutic targets to ensure comparability between future studies, the inter-observer agreement should be determined for all relevant parameters.
Eligibility
Min Age: 18 Years
Inclusion Criteria4
- Crohn's disease evolving for at least 1 months
- Patient older than 18 years
- Patient covered by French national health insurance
- Written informed consent
Exclusion Criteria3
- Pregnant women or breastfeeding
- Minor
- Patient deprived of liberty by administrative or judicial decision or placed under judicial protection (guardianship or supervision)
Interventions
OTHERTransabdominal intestinal ultrasound
Transabdominal intestinal ultrasound
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06833450
Related Trials
Evaluation of Muscle Strength and Muscle Mass in Patients With Inflammatory Bowel Disease
NCT074414471 location
HB-adMSCs for the Treatment of Crohn's Disease
NCT070777461 location
Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)
NCT072453949 locations
ALPCO/Calprotectin CLIA Assay: Expected Values of Calprotectin in Healthy Subjects
NCT070894201 location
Impact of Exclusion Diet in Addition to Anti-TNF Therapy in Crohn's Disease and Ulcerative Colitis: a Prospective, Randomized, Double-arm, Open-label Study
NCT068963051 location